Literature DB >> 3747864

Number of hits necessary for complement-mediated hemolysis.

J Takeda, H Kozono, Y Takata, K Hong, T Kinoshita, K Sayama, E Tanaka, K Inoue.   

Abstract

The number of hits necessary for the C8 and C9 steps of immune hemolysis was reexamined with a previously unemployed experimental design, in which various numbers of EAC1-7, excess of the supplementary component and a constant amount of the component tested were incubated in a constant volume (Inoue et al. 1976. Infect. Immun. 13: 337). Our results were consistent with previous findings; the steps of guinea pig C8 and C9, the human C8 each followed a one-hit mechanism, while that of human C9 showed ka multi-hit response. When lysis of sensitized erythrocytes (EA) by normal human serum was analysed in a similar way, one-hit curves were obtained. This result, taken together with the above results, suggests that immune hemolysis occurs by a single lesion including a single C8 and multiple C9 in the case of human complement and that normal human serum contains sufficient excess of C9. On the other hand, when C9-deficient human serum was used for lysis of EA, multiple-hit curves were obtained. The mechanism of lysis by C5b-8 may differ from that by C5b-9.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3747864     DOI: 10.1111/j.1348-0421.1986.tb02972.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  2 in total

1.  Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation.

Authors:  Hongbin Song; Chun He; Christian Knaak; Joel M Guthridge; V Michael Holers; Stephen Tomlinson
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

2.  Modeling the activation of the alternative complement pathway and its effects on hemolysis in health and disease.

Authors:  Antonello Caruso; Jannik Vollmer; Matthias Machacek; Elod Kortvely
Journal:  PLoS Comput Biol       Date:  2020-10-02       Impact factor: 4.475

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.